

Antonio Macci

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7457395/antonio-maccio-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

102
papers

3,228
citations

32
h-index

55
g-index

111
ext. papers

3,667
ext. citations

3.9
avg, IF

5.11
L-index

#	Paper	IF	Citations
102	Diagnostic Framework of Pelvic Massive Necrosis with Peritonitis following Chemoradiation for Locally Advanced Cervical Cancer: When Is the Surgery Not Demandable? A Case Report and Literature Review.. <i>Diagnostics</i> , 2022 , 12,	3.8	0
101	Next-Generation Sequencing Whole-Genome Analysis for Targeted Treatment Approach of Metastatic Bartholin Gland Adenocarcinoma: An Emblematic Case Report and Review of the Literature. <i>Diagnostics</i> , 2021 , 11,	3.8	0
100	Laparoscopic splenectomy both for primary cytoreductive surgery for advanced ovarian cancer and for secondary surgery for isolated spleen recurrence: feasibility and technique. <i>BMC Surgery</i> , 2021 , 21, 380	2.3	
99	Cachexia as Evidence of the Mechanisms of Resistance and Tolerance during the Evolution of Cancer Disease. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	7
98	Experimental Drugs for Chemotherapy- and Cancer-Related Anemia. <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 593-611	3	2
97	Novel technique of extracorporeal intrauterine morcellation after total laparoscopic hysterectomy: Three emblematic case reports. <i>World Journal of Clinical Cases</i> , 2021 , 9, 5655-5660	1.6	
96	Feasibility and safety of total laparoscopic hysterectomy for uteri weighing from 1.5kg to 11.000kg. <i>Archives of Gynecology and Obstetrics</i> , 2021 , 303, 169-179	2.5	2
95	COVID-19 and cytokine storm syndrome: can what we know about interleukin-6 in ovarian cancer be applied?. <i>Journal of Ovarian Research</i> , 2021 , 14, 28	5.5	5
94	Decrease in Neutrophil-to-Lymphocyte Ratio during Neoadjuvant Chemotherapy as a Predictive and Prognostic Marker in Advanced Ovarian Cancer. <i>Diagnostics</i> , 2021 , 11,	3.8	4
93	Role of M1-polarized tumor-associated macrophages in the prognosis of advanced ovarian cancer patients. <i>Scientific Reports</i> , 2020 , 10, 6096	4.9	57
92	Laparoscopic management of a giant mucinous benign ovarian mass weighing 10150 grams: A case report. <i>World Journal of Clinical Cases</i> , 2020 , 8, 3527-3533	1.6	2
91	Blocking inflammation to improve immunotherapy of advanced cancer. <i>Immunology</i> , 2020 , 159, 357-364	7.8	13
90	Multifactorial pathogenesis of COVID-19-related coagulopathy: Can defibrotide have a role in the early phases of coagulation disorders?. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3106-3108	15.4	7
89	Defibrotide in the COVID-19 coagulopathy: What is the timing?. <i>Journal of Thrombosis and Haemostasis</i> , 2020 , 18, 3113-3115	15.4	2
88	The mechanism of cancer cell death by PARP inhibitors goes beyond DNA damage alone. <i>International Journal of Cancer</i> , 2019 , 145, 2594-2596	7.5	5
87	Laparoscopic hysterectomy as optimal approach for 5400 grams uterus with associated polycythemia: A case report. <i>World Journal of Clinical Cases</i> , 2019 , 7, 3027-3032	1.6	4
86	Next generation sequencing driven successful combined treatment with laparoscopic surgery and immunotherapy for relapsed stage IVB cervical and synchronous stage IV lung cancer. <i>Oncotarget</i> , 2019 , 10, 2012-2021	3.3	2

85	Microenvironmental M1 tumor-associated macrophage polarization influences cancer-related anemia in advanced ovarian cancer: key role of interleukin-6. <i>Haematologica</i> , 2018 , 103, e388-e391	6.6	24
84	Feasibility and safety of total laparoscopic hysterectomy for huge uteri without the use of uterine manipulator: description of emblematic cases. <i>Gynecological Surgery</i> , 2018 , 15, 6	1.7	5
83	Future Prospects for PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Patients With Sarcomas. <i>JAMA Oncology</i> , 2018 , 4, 1134	13.4	4
82	Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. <i>Frontiers in Physiology</i> , 2018 , 9, 1294	4.6	48
81	Abdominal leiomyosarcomatosis after surgery with external morcellation for occult smooth muscle tumors of uncertain malignant potential: A case report. <i>International Journal of Surgery Case Reports</i> , 2017 , 38, 107-110	0.8	6
80	Laparoscopic removal of a very large uterus weighting 5320g is feasible and safe: a case report. <i>BMC Surgery</i> , 2017 , 17, 50	2.3	9
79	Long-Term Survival in a Patient With Abdominal Sarcomatosis From Uterine Leiomyosarcoma: Role of Repeated Laparoscopic Surgery in Treatment and Follow-Up. <i>Journal of Minimally Invasive Gynecology</i> , 2016 , 23, 1003-8	2.2	2
78	Combined laparoscopic excisional surgery for synchronous endometrial and rectal adenocarcinoma in an obese woman. <i>Journal of Obstetrics and Gynaecology</i> , 2016 , 36, 1012-1015	1.3	
77	Surgical outcome and complications of total laparoscopic hysterectomy for very large myomatous uteri in relation to uterine weight: a prospective study in a continuous series of 461 procedures. <i>Archives of Gynecology and Obstetrics</i> , 2016 , 294, 525-31	2.5	21
76	Muscle wasting as main evidence of energy impairment in cancer cachexia: future therapeutic approaches. <i>Future Oncology</i> , 2015 , 11, 2697-2710	3.6	18
75	Advances in pharmacologic strategies for cancer cachexia. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2163-77	4	21
74	A Multitargeted Treatment Approach for Anemia and Cachexia in Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Pain and Symptom Management</i> , 2015 , 50, e1-4	4.8	6
73	Surprising results of a supportive integrated therapy in myelofibrosis. <i>Nutrition</i> , 2015 , 31, 239-43	4.8	4
72	The role of inflammation, iron, and nutritional status in cancer-related anemia: results of a large, prospective, observational study. <i>Haematologica</i> , 2015 , 100, 124-32	6.6	114
71	Role of inflammation and oxidative stress in post-menopausal oestrogen-dependent breast cancer. <i>Journal of Cellular and Molecular Medicine</i> , 2014 , 18, 2519-29	5.6	46
70	Large twisted ovarian fibroma associated with Meigs Syndrome, abdominal pain and severe anemia treated by laparoscopic surgery. <i>BMC Surgery</i> , 2014 , 14, 38	2.3	13
69	Ovarian hyperstimulation in premenopausal women during adjuvant tamoxifen treatment for endocrine-dependent breast cancer: A report of two cases. <i>Oncology Letters</i> , 2014 , 8, 1279-1282	2.6	10
68	Successful laparoscopic management of a giant ovarian cyst. <i>Journal of Obstetrics and Gynaecology</i> , 2014 , 34, 651-2	1.3	3

67	Cisplatin : an old drug with a newfound efficacy -- from mechanisms of action to cytotoxicity. <i>Expert Opinion on Pharmacotherapy</i> , 2013 , 14, 1839-57	4	62
66	The role of interleukin-6 in the evolution of ovarian cancer: clinical and prognostic implications--a review. <i>Journal of Molecular Medicine</i> , 2013 , 91, 1355-68	5.5	44
65	Current medications for cancer cachexia 2013 , 34-45		
64	Drugs in development for treatment of patients with cancer-related anorexia and cachexia syndrome. <i>Drug Design, Development and Therapy</i> , 2013 , 7, 645-56	4.4	14
63	Efficacy and safety of a two drug-combination regimen for cancer-related cachexia in the clinical practice.. <i>Journal of Clinical Oncology</i> , 2013 , 31, e20556-e20556	2.2	
62	A randomized phase III clinical trial of a combined treatment for cachexia in patients with gynecological cancers: evaluating the impact on metabolic and inflammatory profiles and quality of life. <i>Gynecologic Oncology</i> , 2012 , 124, 417-25	4.9	96
61	Inflammation and ovarian cancer. <i>Cytokine</i> , 2012 , 58, 133-47	4	196
60	Three cases of laparoscopic myomectomy performed during pregnancy for pedunculated uterine myomas. <i>Archives of Gynecology and Obstetrics</i> , 2012 , 286, 1209-14	2.5	12
59	L-Carnitine: an adequate supplement for a multi-targeted anti-wasting therapy in cancer. <i>Clinical Nutrition</i> , 2012 , 31, 889-95	5.9	29
58	Antioxidants, Anorexia/Cachexia, and Oxidative Stress in Patients with Advanced-Stage Cancer 2012 , 373-385		
57	Successful pregnancy following myomectomy of a giant uterine myoma: role of a combined surgical approach. <i>Archives of Gynecology and Obstetrics</i> , 2012 , 285, 1577-80	2.5	4
56	Randomized phase III clinical trial of a combined treatment with carnitine + celecoxib □ megestrol acetate for patients with cancer-related anorexia/cachexia syndrome. <i>Clinical Nutrition</i> , 2012 , 31, 176-82 ^{5.9}	5.9	89
55	Cachexia and oxidative stress in cancer: an innovative therapeutic management. <i>Current Pharmaceutical Design</i> , 2012 , 18, 4813-8	3.3	16
54	Current pharmacotherapy options for cancer anorexia and cachexia. <i>Expert Opinion on Pharmacotherapy</i> , 2012 , 13, 2453-72	4	33
53	Management of anemia of inflammation in the elderly. <i>Anemia</i> , 2012 , 2012, 563251	1.6	30
52	Multitargeted treatment of cancer cachexia. <i>Critical Reviews in Oncogenesis</i> , 2012 , 17, 305-14	1.3	18
51	Krill oil to improve blood lipids status in advanced cancer patient with cachexia.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e19634-e19634	2.2	0
50	Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. <i>Scientific World Journal, The</i> , 2011 , 11, 2020-36	2.2	64

49	Efficacy and safety of oral lactoferrin supplementation in combination with rHuEPO-beta for the treatment of anemia in advanced cancer patients undergoing chemotherapy: open-label, randomized controlled study. <i>Oncologist</i> , 2010 , 15, 894-902	5.7	41
48	Randomized phase III clinical trial of five different arms of treatment in 332 patients with cancer cachexia. <i>Oncologist</i> , 2010 , 15, 200-11	5.7	146
47	Phase II nonrandomized study of the efficacy and safety of COX-2 inhibitor celecoxib on patients with cancer cachexia. <i>Journal of Molecular Medicine</i> , 2010 , 88, 85-92	5.5	97
46	Correlation of body mass index and leptin with tumor size and stage of disease in hormone-dependent postmenopausal breast cancer: preliminary results and therapeutic implications. <i>Journal of Molecular Medicine</i> , 2010 , 88, 677-86	5.5	77
45	Open phase II study on efficacy and safety of an oral amino acid functional cluster supplementation in cancer cachexia. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2010 , 3, 165-172	1.3	4
44	New perspective on the nutritional approach to cancer-related anorexia/cachexia: preliminary results of a randomised phase III clinical trial with five different arms of treatment. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009 , 2, 29-36	1.3	1
43	Interleukin-6 and leptin as markers of energy metabolic changes in advanced ovarian cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2009 , 13, 3951-9	5.6	31
42	New perspective on the nutritional approach to cancer-related anorexia/cachexia: preliminary results of a randomised phase III clinical trial with five different arms of treatment. <i>Mediterranean Journal of Nutrition and Metabolism</i> , 2009 , 2, 29-36	1.3	1
41	Use of erythropoiesis stimulating agents for the treatment of anaemia and related fatigue in a pregnant woman with HbH disease. <i>British Journal of Haematology</i> , 2009 , 146, 335-7	4.5	10
40	Medroxyprogesterone acetate in the management of cancer cachexia. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 1359-66	4	36
39	Carbocysteine: clinical experience and new perspectives in the treatment of chronic inflammatory diseases. <i>Expert Opinion on Pharmacotherapy</i> , 2009 , 10, 693-703	4	16
38	Randomized phase III clinical trial of five different arms of treatment for patients with cancer cachexia: interim results. <i>Nutrition</i> , 2008 , 24, 305-13	4.8	74
37	Evidence that human serum with high levels of estrogens interferes with immune system both by decreasing CD25 expression on T-cell and by increasing interleukin-2 availability. <i>Reproductive Sciences</i> , 2008 , 15, 961-9	3	2
36	An Innovative Treatment Approach for Cancer-Related Anorexia/Cachexia and Oxidative Stress: Background and Design of an Ongoing, Phase III, Randomized Clinical Trial. <i>Supportive Cancer Therapy</i> , 2007 , 4, 163-7		2
35	Antioxidant Therapy for the Treatment of Oxidative Stress Associated to Cancer and Cancer-Related Anorexia/Cachexia. <i>Current Nutrition and Food Science</i> , 2007 , 3, 184-193	0.7	4
34	Efficacy of l-carnitine administration on fatigue, nutritional status, oxidative stress, and related quality of life in 12 advanced cancer patients undergoing anticancer therapy. <i>Nutrition</i> , 2006 , 22, 136-45	4.8	137
33	A phase II study with antioxidants, both in the diet and supplemented, pharmacnutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/cachexia and oxidative stress. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006 , 15, 1030-4	4	124
32	A Phase II Study with Antioxidants, both in the Diet and Supplemented, Pharmaco-Nutritional Support, Progestagen and Anti-COX-2 Showing Efficacy and Safety in Patients with Cancer-Related Anorexia-Cachexia and Oxidative Stress 2006 , 685-698		

31	Glucose Metabolism 2006 , 195-203		2
30	Hemoglobin levels correlate with interleukin-6 levels in patients with advanced untreated epithelial ovarian cancer: role of inflammation in cancer-related anemia. <i>Blood</i> , 2005 , 106, 362-7	2.2	100
29	Selenium is effective in inducing lymphocyte progression through cell cycle in cancer patients: potential mechanisms for its activity. <i>Journal of Experimental Therapeutics and Oncology</i> , 2004 , 4, 69-78	0.8	17
28	Cancer-related anorexia/cachexia syndrome and oxidative stress: an innovative approach beyond current treatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2004 , 13, 1651-9	4	44
27	Cancer-related cachexia and oxidative stress: beyond current therapeutic options. <i>Expert Review of Anticancer Therapy</i> , 2003 , 3, 381-92	3.5	11
26	Phase II clinical trial of local use of GM-CSF for prevention and treatment of chemotherapy- and concomitant chemoradiotherapy-induced severe oral mucositis in advanced head and neck cancer patients: an evaluation of effectiveness, safety and costs. <i>Oncology Reports</i> , 2003 , 10, 197	3.5	2
25	Antioxidant agents are effective in inducing lymphocyte progression through cell cycle in advanced cancer patients: assessment of the most important laboratory indexes of cachexia and oxidative stress. <i>Journal of Molecular Medicine</i> , 2003 , 81, 664-73	5.5	95
24	Subcutaneous interleukin-2 in combination with medroxyprogesterone acetate and antioxidants in advanced cancer responders to previous chemotherapy: phase II study evaluating clinical, quality of life, and laboratory parameters. <i>Journal of Experimental Therapeutics and Oncology</i> , 2003 , 3, 205-19	0.8	22
23	The impact of different antioxidant agents alone or in combination on reactive oxygen species, antioxidant enzymes and cytokines in a series of advanced cancer patients at different sites: correlation with disease progression. <i>Free Radical Research</i> , 2003 , 37, 213-23	4	68
22	Reactive oxygen species, antioxidant mechanisms, and serum cytokine levels in cancer patients: impact of an antioxidant treatment. <i>Journal of Environmental Pathology, Toxicology and Oncology</i> , 2003 , 22, 17-28	2.1	45
21	Quantitative evaluation of oxidative stress, chronic inflammatory indices and leptin in cancer patients: correlation with stage and performance status. <i>International Journal of Cancer</i> , 2002 , 98, 84-91	7.5	115
20	Induction chemotherapy followed by concomitant chemoradiation therapy in advanced head and neck cancer: A phase II study for organ-sparing purposes evaluating feasibility, effectiveness and toxicity 2002 , 20, 419		2
19	Dose-intense phase II study of weekly cisplatin and epidoxorubicin plus medroxyprogesterone acetate and recombinant interleukin 2 in stage IIIB-IV non-small cell lung cancer. <i>Oncology Reports</i> , 2002 , 9, 661	3.5	
18	Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. <i>Oncology Reports</i> , 2002 , 9, 887	3.5	1
17	Phase II study of subcutaneously administered interleukin-2 in combination with medroxyprogesterone acetate and antioxidant agents as maintenance treatment in advanced cancer responders to previous chemotherapy. <i>Oncology Reports</i> , 2002 , 9, 887-96	3.5	12
16	Serum values of proinflammatory cytokines are inversely correlated with serum leptin levels in patients with advanced stage cancer at different sites. <i>Journal of Molecular Medicine</i> , 2001 , 79, 406-14	5.5	70
15	Immunotherapy (recombinant interleukin 2), hormone therapy (medroxyprogesterone acetate) and antioxidant agents as combined maintenance treatment of responders to previous chemotherapy 2001 , 18, 383		1
14	Managing cancer-related anorexia/cachexia. <i>Drugs</i> , 2001 , 61, 499-514	12.1	129

13	Results of a dose-intense phase 1 study of a combination chemotherapy regimen with cisplatin and epidoxorubicin including medroxyprogesterone acetate and recombinant interleukin-2 in patients with inoperable primary lung cancer. <i>Journal of Immunotherapy</i> , 2000 , 23, 267-74	5	11
12	Restoration of functional defects in peripheral blood mononuclear cells isolated from cancer patients by thiol antioxidants alpha-lipoic acid and N-acetyl cysteine. <i>International Journal of Cancer</i> , 2000 , 86, 842-7	7.5	34
11	Serum levels of leptin and proinflammatory cytokines in patients with advanced-stage cancer at different sites. <i>Journal of Molecular Medicine</i> , 2000 , 78, 554-61	5.5	165
10	High serum levels of soluble IL-2 receptor, cytokines, and C reactive protein correlate with impairment of T cell response in patients with advanced epithelial ovarian cancer. <i>Gynecologic Oncology</i> , 1998 , 69, 248-52	4.9	76
9	Cytokine involvement in cancer anorexia/cachexia: role of megestrol acetate and medroxyprogesterone acetate on cytokine downregulation and improvement of clinical symptoms. <i>Critical Reviews in Oncogenesis</i> , 1998 , 9, 99-106	1.3	85
8	Medroxyprogesterone acetate reduces the production of cytokines and serotonin involved in anorexia/cachexia and emesis by peripheral blood mononuclear cells of cancer patients. <i>Biochemical Society Transactions</i> , 1997 , 25, 296S	5.1	8
7	Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines. <i>International Journal of Cancer</i> , 1997 , 71, 724-31	7.5	30
6	Comparison of granisetron, ondansetron, and tropisetron in the prophylaxis of acute nausea and vomiting induced by cisplatin for the treatment of head and neck cancer: a randomized controlled trial. <i>Cancer</i> , 1996 , 77, 941-948	6.4	55
5	Membrane-bound/soluble IL-2 receptor (IL-2R) and levels of IL-1 alpha, IL-2, and IL-6 in the serum and in the PBMC culture supernatants from 17 patients with hematological malignancies. <i>Cell Biophysics</i> , 1995 , 27, 1-14		3
4	Preovulatory human follicular fluid in vitro inhibits interleukin (IL)-1 alpha, IL-2, and production and expression of p55 chain IL-2 receptor of lymphomonocytes. <i>Fertility and Sterility</i> , 1994 , 62, 327-32	4.8	10
3	Evidence that granulosa cells inhibit interleukin-1 alpha and interleukin-2 production from follicular lymphomonocytes. <i>Journal of Assisted Reproduction and Genetics</i> , 1993 , 10, 517-22	3.4	11
2	Membrane-bound and soluble IL-2 receptors (p55 and p75 chains) on peripheral blood mononuclear cells from patients with solid malignancies. <i>Cell Biophysics</i> , 1993 , 22, 79-99		5
1	Effects of antiestrogen and progestin on immune functions in breast cancer patients. <i>Cancer</i> , 1988 , 61, 2214-8	6.4	18